the programme

ESMO Preceptorship on Colorectal Cancer
Multidisciplinary management, standards of care and future perspectives
March 27-28th 2015, SINGAPORE
Co-Chairs:
Jean-Yves Douillard, France
Claus-Henning Köhne, Germany
LEARNING OBJECTIVES
 To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and
metastatic settings
 To understand the importance of pathology and histoprognostic factors
 To learn about the management of patients after progression, side-effects of treatments, and in special situations
Friday, 27th March 2015
09:00-9:15
Welcome and introduction
09:15 ‐10:50 Session 1
95’
Early colorectal cancer
30‘
The point of view of the pathologist
- Quality and rules of a good pathology report
- Histoprognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic
infiltration, MSH expression
20’
State‐of‐the‐art: Standard of surgical practice for resectable colo‐rectal cancer (special issues on
rectal cancer)
30’
State‐of‐the‐art: Standard(s) of perioperative radio/chemotherapy for rectal cancer
15’
Discussion
10:50-11:10 Coffee Break
11:10-13:00 Session 2
105‘
Adjuvant settings of colorectal cancer
30‘
Microsatellite instability: Where do we stand? How useful is it?
30‘
Adjuvant treatment for colon cancer III
Page 1 of 3
esmo.org
30‘
Adjuvant treatment of stage II Which patients to treat?
20‘
Discussion
13:00-14:00 LUNCH
60‘
14:00-14:30 Session 3
30’
Clinical cases
30‘
2 Clinical cases from participants (10‘/case + 5’discussion)
14:30-16:15 Session 4: Metastatic colorectal cancer, liver limited metastases
105‘
15‘
Review of the ESMO consensus conference on metastatic colorectal cancer
- Basic strategies and groups (RASwt /mut, BRAF mut)
15’
Development of conventional chemotherapy in mCRC,
BSC vs, Chemo, biochemical modulation, oral fluoropyrimidines, development of combination
chemotherapy
30‘
Resection of liver limited metastasis (Resectable cases, Group 0)
- Upfront
- After neo-adjuvant treatment
- Repeated hepatectomy
30‘
Unresectable or borderline resectable (Group 1) chemotherapy +/- targetd agents
15‘
Discussion
16:15-16:45 Coffee Break
16:45-18:30 Session 5
105‘
Special clinical situations: Mono- or oligometastatic disease
30‘
Treatment of metastatic disease confined to the peritoneum
- Resection
- HIPEC
- PIPEC
30‘
Options of locoregional treatment of liver metastasis
- intraarterial therapy
- chemoembolisation
- SIRT
- Local radiation
30‘
Primary with synchroneous metastases
15‘
Discussion
Page 2 of 3
esmo.org
Time TBC
Dinner
Saturday, 28 May 2014
09:00-10:30 Session 6
90‘
Metastatic colorectal cancer I
25‘
The role of EGFR inhibition in mCRC
25‘
The role of VEGF inhibition in mCRC
10‘
Discussion
25‘
The role of maintenance, appropriate endpoints according to ESMO consensus
5‘
Discussion
10:30-11:00
Coffee Break
11:00-12:15 Session 7
75‘
Metastatic colorectal cancer II
30‘
- The Continuum of Care in colorectal cancer versus lines of treatment
- Appropriate use of new agents (aflibercept and regorafenib) within the treatment algorithm
- Re-introduction of regimens?
30‘
Management of treatment related side effects
- GI-Toxicity
- Neuropathy
- Skin toxicity
- Hypertension
Hand-foot syndrome
15‘
Discussion
12:15-13:00 Session 8
45‘
Case presentations from participants followed by panel discussion
3X15‘
3 Clinical cases from participants (10‘/case + 5’discussion)
13:00-13:15 Conclusion and farewell
15‘
13:15-14:00 LUNCH
Page 3 of 3
esmo.org